Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Recruiting
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/22/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Type 2 Diabetes Mellitus, Cardiovascular Diseases
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
Completed
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2017
Locations: GSK Investigational Site, Dearborn, Michigan +4 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
Completed
This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2017
Locations: GSK Investigational Site, Bloomfield Hills, Michigan +5 locations
Conditions: Diabetes Mellitus, Type 2